Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868595 · ClinicalTrials.gov registry record · Phase 1
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
A Phase 1 study, sponsored by Bellicum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00868595 is a Phase 1 study that has completed, run by Bellicum Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT00868595, a Phase 1 study, has completed, sponsored by Bellicum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in patients with castrate resistant prostate cancer.
Interventions
- DRUG AP1903
- BIOLOGICAL BPX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868595
The ClinicalTrials.gov registry entry for NCT00868595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AP1903 is the first listed.
NCT00868595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868595 about?
NCT00868595 is a clinical study titled "MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer". This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in patients with castrate resistant prost...
What is the current status of trial NCT00868595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00868595?
The interventions under investigation include: AP1903 (DRUG), BPX-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00868595?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.